REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients Philip McCarthy, MD, Director of the Blood and Marrow Transplant Center at Roswell Park Comprehensive Cancer Center in Buffalo, NY, comments on the U.S. Food and Drug Administration (FDA)’s approval of REVLIMID (lenalidomide) maintenance therapy, after autologous stem cell transplant, for multiple myeloma. Dr. McCarthy, who […]

Read More